Still Coughing: Now-Dominant COVID-19 Variant Can Elude Current Vaccines, Prompts FDA Action

SS
Seyfarth Shaw LLP
Contributor
With more than 900 lawyers across 18 offices, Seyfarth Shaw LLP provides advisory, litigation, and transactional legal services to clients worldwide. Our high-caliber legal representation and advanced delivery capabilities allow us to take on our clients’ unique challenges and opportunities-no matter the scale or complexity. Whether navigating complex litigation, negotiating transformational deals, or advising on cross-border projects, our attorneys achieve exceptional legal outcomes. Our drive for excellence leads us to seek out better ways to work with our clients and each other. We have been first-to-market on many legal service delivery innovations-and we continue to break new ground with our clients every day. This long history of excellence and innovation has created a culture with a sense of purpose and belonging for all. In turn, our culture drives our commitment to the growth of our clients, the diversity of our people, and the resilience of our workforce.
Omicron BA5 strain has become dominant and has evolved to render vaccinations and boosters less effective, resulting in many employers revisiting their COVID-19 policies.
United States Employment and HR
To print this article, all you need is to be registered or login on Mondaq.com.

Seyfarth Synopsis: Omicron BA5 strain has become dominant and has evolved to render vaccinations and boosters less effective, resulting in many employers revisiting their COVID-19 policies.

According to the Centers for Disease Control and Prevention (CDC), "SARS-CoV-2, the virus that causes COVID-19, is constantly changing and accumulating mutations in its genetic code over time. New variants of SARS-CoV-2 are expected to continue to emerge. Some variants will emerge and disappear, while others will emerge and continue to spread and may replace previous variants." For instance, a new version of COVID, omicron is dominant in the U.S. As of last Saturday, the coronavirus subvariant known as Omicron BA.5 accounted for nearly 54% of the country's COVID cases, according to the CDC. A similar subvariant, BA.4, makes up approximately 17% more. Studies further indicate that COVID-19 reinfections are associated with lasting health effects and long COVID symptoms.

The FDA has noted that vaccines and boosters currently available are significantly less effective against these new variants, and the agency is working with vaccine manufacturers to tailor boosters to address these inadequacies, as well as to anticipate further evolution of the virus. On June 30, 2022, after a June 28 discussion and vote by the Vaccines and Related Biological Products Advisory Committee, the FDA issued a statement explaining that it

advised manufacturers seeking to update their COVID-19 vaccines that they should develop modified vaccines that add an omicron BA.4/5 spike protein component to the current vaccine composition to create a two component (bivalent) booster vaccine, so that the modified vaccines can potentially be used starting in early to mid-fall 2022.

The FDA appears to have based this recommendation on its determination "that vaccines . . . need to be modified to address circulating variants."

While federal and state OSHA agencies continue to conduct inspections and issue citations relating to COVID-19 hazards, federal OSHA largely has abrogated its leadership in protecting employees from COVID-19, failing to advise employers on how to address new strains or issue employers any updated guidance since August 13, 2021, despite the long-standing promise of an "UPDATE COMING SOON." The prospect of new strains of COVID-19, reinfections, and lasting health effects have led many employers to revisit their COVID-19 precautions and policies. Employers with vaccination requirements continue to update those policies, including new booster requirements to ensure employee safety from new variants.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

Still Coughing: Now-Dominant COVID-19 Variant Can Elude Current Vaccines, Prompts FDA Action

United States Employment and HR
Contributor
With more than 900 lawyers across 18 offices, Seyfarth Shaw LLP provides advisory, litigation, and transactional legal services to clients worldwide. Our high-caliber legal representation and advanced delivery capabilities allow us to take on our clients’ unique challenges and opportunities-no matter the scale or complexity. Whether navigating complex litigation, negotiating transformational deals, or advising on cross-border projects, our attorneys achieve exceptional legal outcomes. Our drive for excellence leads us to seek out better ways to work with our clients and each other. We have been first-to-market on many legal service delivery innovations-and we continue to break new ground with our clients every day. This long history of excellence and innovation has created a culture with a sense of purpose and belonging for all. In turn, our culture drives our commitment to the growth of our clients, the diversity of our people, and the resilience of our workforce.
See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More